Open AccessA multi‐biomarker follow‐up study of patients with multiple sclerosis
Author(s) -
Stilund Morten,
Gjelstrup Mikkel Carstensen,
Christensen Tove,
Møller Holger Jon,
Petersen Thor
Publication year - 2016
Publication title -
brain and behavior
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.915
H-Index - 41
ISSN - 2162-3279
DOI - 10.1002/brb3.509
Subject(s) - multiple sclerosis , clinically isolated syndrome , medicine , cerebrospinal fluid , biomarker , gastroenterology , osteopontin , disease , pathology , oncology , immunology , biochemistry , chemistry
Objectives This study aimed to examine the levels of the macrophage marker sCD 163 and other biomarkers at the time of diagnosis of patients with either clinically isolated syndrome ( CIS ) or relapsing‐remitting multiple sclerosis ( RRMS ), and assess relation to clinical indicators of prognosis, disease activity ( DA ), and changes in the levels of these biomarkers at follow‐up. Materials and Methods The clinical status and MRI were reevaluated in 56 patients more than 1 year after diagnosis with a median follow‐up time of 2 years. Levels of biomarkers in serum and cerebrospinal fluid ( CSF ) samples were evaluated by enzyme‐linked immunosorbent assays. Results There was no significant difference in time to DA between patients with CIS and RRMS . A high sCD 163 ratio (>0.07) was significantly ( P = 0.04) associated with time to DA in the untreated patient group. In 21 patients reevaluated with serum and CSF samples, the sCD 163 ratio levels decreased from 0.068 to 0.054 ( P = 0.026) in the CIS / RRMS ‐treated group. The CSF CXCL 13, CXCL 13 ratio, CSF neurofilament light polypeptide and osteopontin levels also decreased significantly in the CIS / RRMS ‐treated group. Conclusions The levels of all biomarkers changed concurrently with MS treatment. The sCD 163 ratio was identified as a potential novel marker for time to DA .